Page 42 - Read Online

Page 14 of 15 Benhammou et al. Hepatoma Res 2020;6:35 I http://dx.doi.org/10.20517/2394-5079.2020.16

81. Kim G, Jang SY, Nam CM, Kang ES. Statin use and the risk of hepatocellular carcinoma in patients at high risk: a nationwide nested
case-control study. J Hepatol 2018;68:476-84.
82. Friedman GD, Achacoso N, Fireman B, Habel LA. Statins and reduced risk of liver cancer: evidence for confounding. J Natl Cancer Inst
2016;108.
83. Yi C, Song Z, Wan M, Chen Y, Cheng X. Statins intake and risk of liver cancer: a dose-response meta analysis of prospective cohort
studies. Medicine (Baltimore) 2017;96:e7435.
84. Shi M, Zheng H, Nie B, Gong W, Cui X. Statin use and risk of liver cancer: an update meta-analysis. BMJ Open 2014;4:e005399.
85. Ogura S, Yoshida Y, Kurahashi T, Egawa M, Furuta K, et al. Targeting the mevalonate pathway is a novel therapeutic approach to inhibit
oncogenic FoxM1 transcription factor in human hepatocellular carcinoma. Oncotarget 2018;9:21022-35.
86. Gruenbacher G, Thurnher M. Mevalonate metabolism governs cancer immune surveillance. Oncoimmunology 2017;6:e1342917.
87. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an
international consensus statement. Lancet Oncol 2009;10:501-7.
88. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: a summary review to 2007. Recent Results Cancer Res 2009;181:231-51.
89. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt
activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003;38:756-68.
90. Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, et al. Nonsteroidal anti-inflammatory drug use, chronic liver
disease, and hepatocellular carcinoma. J Natl Cancer Inst 2012;104:1808-14.
91. Schatzkin A, Subar AF, Thompson FE, Harlan LC, Tangrea J, et al. Design and serendipity in establishing a large cohort with wide dietary
intake distributions : the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol
2001;154:1119-25.
92. Petrick JL, Sahasrabuddhe VV, Chan AT, Alavanja MC, Beane-Freeman LE, et al. NSAID use and risk of hepatocellular carcinoma and
intrahepatic cholangiocarcinoma: the liver cancer pooling project. Cancer Prev Res (Phila) 2015;8:1156-62.
93. Carpino G, Del Ben M, Pastori D, Carnevale R, Baratta F, et al. Increased liver localization of lipopolysaccharides in human and
experimental non-alcoholic fatty liver disease. Hepatology 2019; Epub ahead of print. doi: 10.1002/hep.31056.
94. Paik JM, Henry L, De Avila L, Younossi E, Racila A, et al. Mortality related to nonalcoholic fatty liver disease is increasing in the United
States. Hepatol Commun 2019;3:1459-71.
95. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, et al. Metagenomic analysis of the human distal gut microbiome. Science
2006;312:1355-9.
96. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, et al. Increased intestinal permeability and tight junction alterations in
nonalcoholic fatty liver disease. Hepatology 2009;49:1877-87.
97. Volynets V, Küper MA, Strahl S, Maier IB, Spruss A, et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in
patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci 2012;57:1932-41.
98. Noverr MC, Huffnagle GB. Does the microbiota regulate immune responses outside the gut? Trends Microbiol 2004;12:562-8.
99. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism
2016;65:1038-48.
100. Mouzaki M, Wang AY, Bandsma R, Comelli EM, Arendt BM, et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PLoS
One 2016;11:e0151829.
101. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and
obesity. Nature 2012;482:179-85.
102. Boursier J, Diehl AM. Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog 2015;11:e1004559.
103. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients:
a connection between endogenous alcohol and NASH. Hepatology 2013;57:601-9.
104. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022-3.
105. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, et al. The severity of nonalcoholic fatty liver disease is associated with gut
dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016;63:764-75.
106. Loomba R, Seguritan V, Li W, Long T, Klitgord N, et al. Gut microbiome-based metagenomic signature for non-invasive detection of
advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 2019;30:607.
107. Grąt M, Wronka KM, Krasnodębski M, Masior Ł, Lewandowski Z, et al. Profile of gut microbiota associated with the presence of
hepatocellular cancer in patients with liver cirrhosis. Transplant Proc 2016;48:1687-91.
108. Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology 2014;59:328-39.
109. Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, et al. Hepatocellular carcinoma is associated with gut microbiota profile and
inflammation in nonalcoholic fatty liver disease. Hepatology 2019;69:107-20.
110. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. Enterohepatic circulation: physiological, pharmacokinetic and clinical
implications. Clin Pharmacokinet 2002;41:751-90.
111. Jacobs JP, Dong TS, Agopian V, Lagishetty V, Sundaram V, et al. Microbiome and bile acid profiles in duodenal aspirates from patients
with liver cirrhosis: the Microbiome, Microbial Markers and Liver Disease Study. Hepatol Res 2018;48:1108-17.
112. Chung GE, Yoon JH, Lee JH, Kim HY, Myung SJ, et al. Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to
suppression of hepatocellular carcinoma cell growth. Oncol Rep 2011;25:1739-46.
113. Liu H, Xu HW, Zhang YZ, Huang Y, Han GQ, et al. Ursodeoxycholic acid induces apoptosis in hepatocellular carcinoma xenografts in
mice. World J Gastroenterol 2015;21:10367-74.